Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Shares in biotech firm Moderna (NASDAQ: MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to ...

Moderna’s ( NASDAQ: MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good ...

Shares started out the week mixed in Asia after U.S. stocks fell to their worst loss since Election Day. Japan’s Nikkei 225 index dropped 1% to 38,255.65 as the yen regained some strength against the ...

Pfizer's stock dropped 4.3 percent while Moderna's fell 3.1 percent and Novavax saw a 2.8 percent dip in its stock Friday ...

( NewsNation) — Shares in some pharmaceutical and biotechnology companies, including those that manufacture vaccines, fell ...

If you missed the early fall push for flu and COVID-19 vaccines, it’s not too late. Health officials say it’s important to ...

President-elect Donald Trump said he’s tapping Robert F. Kennedy Jr. to run the Department of Health and Human Services, a ...

U.S. stocks fell to their worst loss since Election Day as the boost that Wall Street got from last week’s victory for Donald ...

Elon Musk is starting to seriously annoy some in Donald Trump’s inner circle.

Donald Trump has delivered a blow to the drug makers he claims hampered his 2020 election bid with the appointment of vaccine ...

The inability of COVID vaccines to reach the long-lived plasma cell compartment in the bone marrow may explain their waning ...